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a  b  s  t  r  a  c  t
Despite  years  of  biannual  mass  vaccination  of  cattle,  foot-and-mouth  disease  (FMD)  remains  uncontrolled
in  Anatolian  Turkey.  To evaluate  protection  after  mass  vaccination  we  measured  post-vaccination  anti-
bodies in a cohort  of cattle  (serotypes  O,  A  and  Asia-1).  To  obtain  results  reflecting  typical  field  protection,
participants  were  randomly  sampled  from  across  Central  and  Western  Turkey  after  routine  vaccination.
Giving  two-doses  one  month  apart  is recommended  when  cattle  are  first  vaccinated  against  FMD.  How-
ever, due  to cost  and  logistics,  this  is not  routinely  performed  in  Turkey,  and  elsewhere.  Nested  within
the  cohort,  we  conducted  a  randomised  trial comparing  post-vaccination  antibodies  after  a single-dose
versus  a two-dose  primary  vaccination  course.
Four  to five  months  after  vaccination,  only  a third  of single-vaccinated  cattle  had  antibody  levels  above
a  threshold  associated  with  protection.  A  third  never  reached  this  threshold,  even at peak  response  one
month after  vaccination.  It was  not  until  animals  had  received  three  vaccine  doses  in their  lifetime,
vaccinating  every  six  months,  that  most  (64%  to 86% depending  on  serotype)  maintained  antibody  levels
above  this  threshold.  By  this  time  cattle  would  be  >20  months  old  with  almost  half  the  population  below
this  age.  Consequently,  many  vaccinated  animals  will  be  unprotected  for much  of  the year.  Compared
to  a  single-dose,  a primary  vaccination  course  of two-doses  greatly  improved  the  level  and  duration  of
immunity.  We  concluded  that  the  FMD  vaccination  programme  in  Anatolian  Turkey  did  not  produce
the  high  levels  of  immunity  required.  Higher  potency  vaccines  are  now  used  throughout  Turkey,  with  a
two-dose  primary  course  in certain  areas.
Monitoring  post-vaccination  serology  is  an  important  component  of  evaluation  for  FMD  vaccination
programmes.  However,  consideration  must  be given  to which  antigens  are  present  in the  test,  the vaccine
and  the  field  virus.  Differences  between  these  antigens  affect  the  relationship  between  antibody  titre  and
protection.
© 2014  The  Authors.  Published  by  Elsevier  Ltd. This  is an  open  access  article  under  the CC  BY-NC-ND. Introduction
As the duration of FMD  vaccine protection is short lived, ani-
als require regular revaccination. In Turkey cattle are routinely
accinated twice a year [1–4]. It is recommended that after ini-
ial vaccination at two months of age, cattle receive a second dose
ne month later. However, as mass vaccination is costly [5], some
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countries, including Turkey, use a single-dose primary vaccination
course.
Much is known about immunity after a single dose of high
potency vaccine used to control outbreaks in free countries [6–10].
However, requirements in this setting differ to the sustained pro-
tection required in endemic countries where standard potency
(≥3PD50) FMD  vaccines are typically used (PD50 ——50% protective
dose). Limited protection after a single dose of ≥3PD50 FMD  vaccine
is not uncommon [4].FMD  structural protein (SP) antibody levels are strongly corre-
lated with protection [11–18]. In this prospective field study, we
assessed post-vaccination SP antibody levels in a cohort of cattle,
vaccinated within the Turkish FMD  vaccination programme, the
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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bjective being to evaluate vaccine protection in the population at
arge. A randomised trial, with two parallel arms was  nested within
he cohort to assess the effect of administering two  vaccine doses
pproximately one to two months apart as opposed to a single dose.
. Materials and methods
.1. Study design and sampling
.1.1. Background and village selection
Households were selected from an FMD  sero-prevalence sur-
ey conducted in Anatolian Turkey in September–November 2012
“autumn”). We  present results of the prospective study only and
ot the sero-prevalence survey. In the survey, cattle were randomly
ampled from each of 1027 villages, randomly selected across
urkey, stratified by region, using the national livestock database
s a sampling frame.
Villages in Central and Western Anatolia conducted routine FMD
accination immediately after sampling. Prospective study eligibil-
ty was restricted to villages that vaccinated one to two months
efore December 2012 (“winter”) for which serology results were
vailable. From these 37 villages, four were inaccessible due to
eavy snow, one could not be sampled as cattle were at grazing
nd a further nine villages were excluded due to inadequate vac-
ination records. This left 98 households in 23 villages, from eight
rovinces, included in this prospective study (see Fig. 1).
.1.2. Sampling
Each household was visited in December 2012 (“winter”) and
gain in late February or early March 2013 (“spring”). During
ecember, all cattle <24 months old present at enrolled households
ere sampled, including those not sampled in the autumn sero-
revalence survey. Those that tested positive for non-structural
rotein (NSP) antibodies at autumn sampling, indicating prior
nfection, were excluded. Vaccines used were purified for NSP
roteins, so, unlike infection, vaccination rarely leads to NSP sero-
ositivity. This differs from SP antibodies which are produced after
nfection or vaccination. Of 736 animals sampled during winter,
55 had been sampled in autumn 2012. Animals were identified by
nique ear-tag numbers, something all Turkish cattle should have.
.1.3. Booster allocation
At winter sampling, half the cattle in each household were givenn additional dose of S¸ ap institute trivalent FMD  vaccine. Animals
ithin a household were divided into two equally sized groups,
alanced in age and prior FMD  vaccination status. One group was
hen randomly selected to receive an additional dose of vaccine
ig. 1. Map  of Turkey showing the location of villages included in the study. As mass va
ome  only from Central and Western Turkey.ine 33 (2015) 805–811
if the last ear-tag digit of the first animal selected was <5; the
other group received no additional vaccination. Animals under two
months of age were not vaccinated. Animals not previously vac-
cinated were randomised separately with one-in-four selected for
vaccination.
2.1.4. Additional information
Farmers and investigators were present during vaccination and
were not blinded. Outcomes were serological and those conducting
the laboratory tests were blinded from the details of the animals
being tested. Study data were only available to T.J.D.Knight-Jones.
Animal housing and location remained unchanged throughout the
study.
2.1.5. Vaccination and sampling procedures
During autumn, animals were sampled and vaccinated by state
veterinary staff. Winter and spring sampling was  conducted by
T.J.D.Knight-Jones, A.N.Bulut and M.Alkan, when animals were
briefly examined and blood sampled, with additional vaccination
for selected animals. Animal and holding details were collected,
including information on prior vaccination, disease, trading and
husbandry. All animals were permanently housed during the study
with turnout for grazing commencing shortly after final sampling.
2.1.6. Vaccines
The ≥3 PD50, NSP purified S¸ ap institute (Ankara, Turkey) triva-
lent FMD  vaccine, contains strains O Panasia II (O Tur 07), A Iran-05
(A TUR 06) and Asia-1 Sindh-08 (Asia-1 TUR 11). Six different vac-
cine batches were used in autumn vaccination. A single batch was
used within a province, with 2 ml  injected intra-muscularly for each
dose. For all winter vaccination a single batch was  used.
2.1.7. Serology
Sera were tested for NSP antibodies (PrioCHECK FMDV NS
ELISA-Prionics, Zurich, Switzerland). Sera were also assessed for SP
antibodies for the vaccine serotypes using the liquid phase blocking
ELISA (LPBE), supplied by The Pirbright Institute, UK.  The strains
of virus used to produce the ELISA antigens (O Manisa, A22 IRQ
24/64 and Asia-1 Shamir) could not be changed and were differ-
ent to the strains used to produce the vaccine. These differences
were antigenically significant, based on serological matching tests
(WRLFMD, The Pirbright Institute).
Sera taken during autumn 2012 sampling were tested for SP
antibodies using a single dilution of 1:102. This titre is associated
with approximately 70% clinical protection [19], assessed by the
vaccine manufacturer and other published studies, the latter using
a homologous test system [20,21]. Sera collected at winter and
ccination was not conducted in Eastern Turkey in autumn 2012 sampled villages
T.J.D. Knight-Jones et al. / Vaccine 33 (2015) 805–811 807
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tig. 2. Flow diagram and timeline, showing for each study group, the number of p
ere  ultimately analysed for the primary outcome.
pring sampling were titrated for SP antibodies at dilutions of 1:32,
:45, 1:64, 1:96, 1:128, 1:192 and 1:256. NSP and LPBE testing were
erformed at the S¸ ap institute, Turkey.
.1.8. Virus neutralisation (VN) tests
To further investigate the significance of mismatch between the
PBE and vaccine antigens, VN tests were performed on a subset
f 31 cattle from two nearby villages, first vaccinated in autumn
012 by the same operator on the same day using the same vaccine
atch. When sampled in spring, it was 109 days since the 18 single
accinated cattle were last vaccinated and 76 days for the 13 cattle
hat received the two-dose primary course.
VN tests were performed at The Pirbright Institute (WRLFMD)
sing the vaccine strains, the LPBE strains and two current field
trains of concern (O India-2001KAR-13, A Iran-05SIS-10). Dilutions
sed were 1 in: 16, 22, 32, 45, 64, 90, 128, 178, 256, 355, 512, 708,
024 and 1413.
.2. Data processing and analysis
.2.1. SP serology
Samples positive for NSP antibodies, produced after prior infec-
ion and not vaccination, were excluded. For cattle first vaccinated
n autumn 2012, those with prior positivity for SP antibodies were
lso excluded.
Differences in SP titres at winter and spring sampling were com-
ared for animals with differing vaccination histories. SP titres were
lso compared for animals of different sex, province and breed.
omparisons were done using unpaired t-tests and boxplots.
Regression modelling was performed to support the univariable
nalysis and is included in the ESM. Data collection sheets, vaccine
atch testing details and a power calculation are also included in
he ESM.
.2.2. Virus neutralisation
A “70% protective” threshold VN titre was derived from Barnett
t al. (2003) [11], i.e. 1:101.71, 1:101.63 and 1:101.89 for serotypes O, A
nd Asia-1 respectively; with 1:102 for LPBE. The proportion above
he protection threshold for LPBE and VN results were compared
sing tests for paired data with confidence intervals produced by
ootstrapping with 1000 samples.
Analysis was done in R [22] with the lme4 package [23].. Results
Except for one commercial dairy farm, all holdings were tradi-
ional small-holdings within villages, where most households keeppants who  were randomly assigned to receive the additional dose of vaccine that
a few cattle. From the 736 cattle initially randomised, only 647 ani-
mals (88%) were re-sampled in spring. Loss to follow-up consisted
of 5 (1%) cattle inadequately sampled and 84 (11%) not available,
mostly sold to provide income, although 23 had lost ear tags and
could not be identified.
3.1. Sample population
Once NSP positive cattle and the few left unvaccinated in
autumn were excluded, 537 cattle remained, with 260 in the addi-
tional winter vaccine group and 277 in the control group. From
these cattle, 384 were unvaccinated prior to autumn and remained
SP negative at autumn sampling; 189 in the additional vaccine
group and 195 controls (Fig. 2).
3.1.1. Sampled population description
Treatment groups were similar with respect to age (p——0.13; Fig.
S1) and prior vaccination. Mean number of doses prior to autumn
2012 vaccination was 0.25 and 0.33 in the intervention and con-
trol groups respectively (p——0.09). Mean time since last vaccination
when sampled in spring was 72 days in the intervention group,
last vaccinated during winter, and 115 days in the control arm, last
vaccinated in autumn.
3.2. Post-vaccination SP serology
The mean LPBE SP titre at spring sampling for serotype O was
173 (or 102.23) (95% CI: 162–184) in the intervention group and 82
(or 101.91) (95% CI: 71–92) in those not vaccinated during winter
(difference——91, 95% CI: 77–106, p < 0.0001). For serotype A, mean
titre was 120 (or 102.08) (95% CI: 109–131) and 52 (or 101.72) (95%
CI: 43–61) in the intervention and control group (difference——67,
95% CI: 54–82, p < 0.0001) and in the same order mean titre was  167
(or 102.22) (95% CI: 157–179) and 83 (or 101.91) (95% CI: 74–92) for
serotype Asia-1 (difference = 84, 95% CI: 70–98, p < 0.0001). Even
after adjusting for differences in time since last vaccination, the
effect of the two-dose primary course was sizable (see regression
modelling, ESM).
Table 1 shows that with no prior vaccination, approximately one
month after autumn vaccination one third had SP titres below 1:102
for serotypes O and Asia-1. Two-thirds had a titre below 1:102 for
serotype A. Come spring, three-quarters of those that received the
extra vaccine dose had titres over 1:102 (serotypes O and Asia-1);
for serotype A over half of this group had above threshold titres.
For those not revaccinated in winter, by spring, two-thirds had a
low titre (<1:102) for all serotypes. Those also vaccinated in spring
2012, six months prior to the study, had slightly higher titres; and
808 T.J.D. Knight-Jones et al. / Vacc
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antibody levels of those vaccinated in both autumn 2011 and spring
2012 were higher still, reducing the benefit of additional winter
vaccination (Table 1, S1, S2 and Fig. 3).
As the two-dose primary course concerns cattle previously
unvaccinated, the effect of the additional winter dose on cattle vac-
cinated before autumn 2012 was less relevant. However, analysis
of all cattle, without exclusion, does not depend upon the accurate
recollection of vaccine history.
3.3. Univariable analysis
3.3.1. Inter-vaccination interval
Previously unvaccinated cattle with a primary course inter-
vaccination interval of 14–30 days had a mean serotype O SP titre
of 140, compared to 61 in autumn-only vaccinated animals belong-
ing to the same households with difference in means of 79 [95% CI:
61–140]. If the interval was 31–74 days, mean titres were 178 in
autumn and winter vaccinated cattle and 74 in those vaccinated
in autumn only with difference in means of 104 [95% CI: 84–124].
For serotype A with a 14–30 day interval, mean titres were 72 and
22 in the treatment and control group with difference in means of
50 [95% CI: 28–72]; with the 31–74 day interval means were 126
and 51 with difference in means of 75 [95% CI: 55–95]. For serotype
Asia-1 with the 14–30 day interval means were 130 and 76 in the
treatment and control group with difference in means of 76 [95%
CI: 44–107], and with the 31–74 day interval, means were 177 and
82 with difference in means of 95 [95% CI: 77–114]. Titres were
similar for inter-vaccination periods between 31 and 74 days (Fig.
S5).
Further univariable analysis and regression modelling are
included in the ESM.
3.4. Virus neutralisation tests
Titres were greater when assessed against the homologous vac-
cine virus than for the heterologous virus used to make the LPBE
(Fig. 4). For serotypes O and A, VN against the heterologous viruses
mirrored protection according to the LPBE, which uses equiva-
lent antigens. However, for Asia-1, more animals had higher titres
according to the LPBE than for VN, even when virus homologous to
the vaccine was  used in the VN (Table 2).
4. Discussion
The rapid decline in immunity post-vaccination left many cattle
susceptible long before the next six-monthly round of vaccination.
The majority of cattle required three doses of vaccine to develop
and maintain adequate antibody levels when vaccinated every six
months. However, an animal will be at least 20 months old before it
will have received three doses. The two-dose primary course incurs
additional costs. However, without it many more young animals
were unprotected for much of the year. This may  not be the case
for higher potency vaccines [6,24]. An increased immune response
with increased time (>30 days) between the two doses of a primary
course has been observed before [1].
Since this study was performed, as well as changing to a two-
dose primary course in certain areas, the routine vaccine has been
changed to a ≥6PD50 vaccine throughout Turkey. With the ≥3PD50
FMD  vaccine, at least three out of every five single vaccinated cat-
tle were likely to be susceptible to FMD  serotypes O and Asia-1
three to four months after vaccination. For serotype A, even more
would be susceptible. A third or more never attain a protective titre.
Short-lived and limited vaccine protection appears to have con-
tributed to the high incidence of FMD  in Turkey despite widespread
vaccination.
T.J.D
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Fig. 3. Boxplots showing winter and spring SP titres for FMD serotypes O, A and Asia-1 from animals that did and did not receive the winter dose of vaccine. Shown separately for animals that had received differing numbers of
vaccine  doses prior to the study. Boxplots show the median (horizontal line), interquartile range (box) and range (whiskers). Group sample sizes are shown above each box and individual data points are marked as grey vertical
dashes.  Titres below the detection threshold were given a value of zero.
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Table 2
Table showing agreement between protection levels estimated by LPBE and virus neutralisation (VN) using the virus homologous to the vaccine (V) and heterologous viruses
including that used for the LPBE antigen (E). The estimated proportion with a VN titre over the 70% protection threshold is shown [11], this has been stratified according to
LPBE  titre. The median difference between the proportion protected (titre≥threshold) according to VN (V) and LPBE is shown in italics with [2.5th and 97.5th percentiles]. 70%
protection thresholds of 1:102 for LPBE and 1:101.71, 1:101.63 and 1:101.89 for VN tests against serotypes O, A and Asia-1 respectively [11]. The minimum dilution for LPBE
was  101.5 (1:32).
VN Virus
VN titre ≥70% protection threshold (%) LPBE titre
≥102 (%)
LPBE <101.5 LPBE >101.5 to –<102 LPBE ≥102 Total
O (V) Panasia II (TUR 07) 2/9 (22%) 9/11 (82%) 11/11 (100%) 22/31 (71%) 11/31 (35%)
Difference [95% CI] 22% [0-50%] 82% [55–100%] 0%a 36% [19–52%]
(E)  Manisa 0/9 (0%) 2/11 (18%) 9/11 (82%) 11/31 (35%)
India-2001KAR-13 1/9 (11%) 1/11 (9%) 6/10 (60%) 8/30 (27%)
A (V)  Iran-05 (TUR 06) 4/16 (25%) 5/7 (71%) 8/8 (100%) 17/31 (55%) 8/31 (26%)
Difference [95% CI] 25% [6–48%] 71% [33–100%] 0%a 29% [16–45%]
(E)  22IRQ 24/64 0/16 (0%) 1/7 (14%) 5/8 (63%) 6/31 (19%)
Iran-05SIS-10 1/16 (6%) 2/6 (33%) 3/8 (38%) 6/30 (20%)
Asia-1 (V)  Sindh-08 (TUR 11) 0/2 (0%) 2/16 (12.5%) 8/13 (62%) 10/31 (32%) 13/31 (42%)
Difference [95% CI] 0% [0–66%]a 12% [0–31%] −39% [−67 to −13%] −10% [−26 to −6%]b
(E) Shamir 0/2 (0%) 0/16 (0%) 2/13 (15%) 2/31 (6%c)
a Bootstrap 95% CI of 0–0% as no variation in original results so binomial proportion used.
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c 13% with titre ≥common O, A, Asia-1 70% protection threshold (1:101.67) which
Vaccines will provide better protection against challenge with
 homologous virus than one antigenically different to the vac-
ine strain, as illustrated by the VN results. At spring sampling,
or serotypes A and O only a third were above the antibody pro-
ection threshold by LPBE whereas half to two-thirds were above protection threshold assessed by VN performed with the vaccine
omologous virus. However, changing a vaccine strain is difficult
nd field viruses with limited vaccine match often arise. The low VN
ig. 4. Log10 (titre) of virus neutralisation tests against the homologous vaccine
irus and the heterologous virus used in the LPBE test. Additional field strains of
oncern were also tested (O India-2001KAR-13 and A Iran-05SIS-10). Results are shown
or serotypes O, A and Asia-1 for sera collected in spring 2013 from 31 cattle first
accinated in Autumn 2012. Original LPBE results are also included. Thresholds for
70% protection are indicated by the dashed lines. Results marked with a “B” are
rom animals given a second vaccine dose one month after autumn vaccination
hereas those marked “V” have only been vaccinated in autumn 2012. Titres below
he  detection threshold were given a value of zero.on O, A, Asia-1 VN threshold (1:101.67) used instead of Asia-1 specific VN threshold
er than the Asia-1 only threshold [11]
titres for the heterologous O India-2001KAR-13 and A Iran-05SIS-10
strains, suggest limited vaccine protection [4].
Contrary to what might be expected, protection against the Asia-
1 serotype estimated by VN with the virus used to produce the
vaccine was  lower than for LPBE using antigen from a strain dif-
ferent to the vaccine strain. VN is less reproducible than LPBE and
assessing protection by serology is never perfect [25]. Also, after
batch release testing (batch 12 06, Fig. S3), the Asia-1 serotype
may have degraded, although serotype O is typically more unsta-
ble. Degraded vaccine elicits more non-neutralising antibody that
reacts in ELISA but not VN.
Field studies of the Asia-1 TUR 11 vaccine during outbreaks of
the TUR11 virus found reasonable protection against clinical dis-
ease after a single dose with vaccine effectiveness of 69% (95%
CI: 50–81%) [26]. Although vaccination reduced the risk, one-in-
three vaccinated cattle still developed FMD  [26]. This was  similar
to the proportion with an Asia-1 SP titre below the LPBE protec-
tion threshold (1:102) at winter sampling, also assessed one to two
months post-vaccination.
When inferring FMD  protection from antibody titre, the sero-
logical test used should be correlated with protection [19]. If a
test antigen is used that differs to the one evaluated in the chal-
lenge study, the extent to which titre will reflect protection is more
uncertain. Although variation in the reactivity of sera against differ-
ent viral strains will reflect variation in the likelihood of protection
[4], we  are currently unable to quantify this variation with confi-
dence. Quantification of protection requires virus challenge, either
in the field or under controlled conditions, and for serological pre-
dictions, protection must be correlated with a specific assay.
Serological protection thresholds are typically derived from
experimental potency tests where a high dose of challenge virus
is injected into the tongue, 3–4 weeks after a single vaccine dose.
The challenge virus is usually homologous to the vaccine and test
strain. Protection in the field may  differ, as virus challenge may be
less intense but often more prolonged, and cattle have often been
vaccinated many times with the last dose given 0–6 months prior
to challenge. Although evaluation during field challenge is recom-
mended [27], differences in SP titre between the vaccine groups
in this study were large enough to expect sizable differences in
susceptibility.
Routinely administered, the two-dose primary course would
incur significant costs. This may  be justifiable as protection in those
<20 months age is greatly improved. This study assessed only cattle
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accinated 1–4 times. There will be many unvaccinated cattle in the
opulation at large, plus older cattle, vaccinated many times. Popu-
ation immunity is complex and changes with population turnover,
overage and the proportion vaccinated multiple times. Further
onsideration requires a modelling approach.
. Conclusion
When cattle in Turkey were vaccinated against FMD  at six-
onthly intervals, only after receiving three doses in their lifetime
id most cattle maintain a high level of antibodies for more than
hree to four months. Thus, cattle under two years old, comprising
0% of the population [28], and many older cattle, appeared suscep-
ible to FMD  for half the year. A third never developed a satisfactory
itre following a single vaccine dose.
Differences in vaccine and serological test antigens influenced
itre, reflecting lower protection when challenged with a poorly
atched field virus. However, in order to predict protection from
erology, the relationship between titre, measured with a particular
est, and protection, against a particular strain, should be quanti-
ed. If not, cases of low population immunity may  still be identified,
owever, the antigenic similarity of the vaccine, the test and the
eld virus should be considered in detail.
Starting vaccination with two vaccine doses, no less than one
onth apart, would dramatically increase population immunity,
articularly in young animals. This is now conducted in certain
rovinces in Turkey and higher potency vaccines (≥6PD50) are now
outinely used throughout the country. Evaluation of this new strat-
gy is required.
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